GlassScriptPhysician profile
Kariappa Mandepanda Appachu
NPI 1942504683
$2,673.53
in general payments reported to CMS, 2019-2025
25 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $141 · 2021: $516 · 2022: $504 · 2023: $286 · 2024: $612 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.95 |
| Education | $100.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $396.01 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $352.20 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $266.74 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $237.81 | 2019-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $225.18 | 2020-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $124.68 | 2021-2025 | |
| Baxter Healthcare | $123.64 | 2024 | |
| Vifor Pharma, INC. | $122.96 | 2019-2023 | Veltassa |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Mallinckrodt Hospital Products INC. | $102.38 | 2020-2024 | Acthar |
| Amgen INC. | $91.20 | 2019-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $76.06 | 2019-2021 | |
| Horizon Therapeutics Plc | $55.77 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $52.56 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $47.36 | 2024 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.73 | 2025 | Jardiance |
| Abiomed | $36.71 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $36.62 | 2021-2025 | |
| Ardelyx, INC. | $34.87 | 2023-2025 | Ibsrela |
| Outset Medical INC | $34.22 | 2023 | |
| Abbott Laboratories | $24.83 | 2023 | Cardiomems |
| Renalytix Ai, INC. | $23.96 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $20.98 | 2022 | |
| Nxstage Medical, INC. | $18.19 | 2023 | Liberty Select Cycler, Nxstage System One |
| Mallinckrodt Enterprises LLC | $16.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kariappa Appachu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.